A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men

Journal of Clinical Endocrinology and Metabolism

Volumn 74, Issue 1, 1992, Pages 75-83

  Bhasin, Shalender ^a   Swerdloff, Ronald S ^a   Steiner, Barbara ^a   Peterson, Margaret A ^a   Meridores, Tessie ^a   Galmirini, Mirta ^b   Pandian, Murugan R ^b   Goldberg, Ronald ^c   Berman, Nancy ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; ARTICLE; BIODEGRADATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION; HUMAN; HYPOGONADISM; MALE; PRIORITY JOURNAL;

ANDROGENS; BIOLOGY; CLINICAL RESEARCH; ENDOCRINE SYSTEM; EXAMINATIONS AND DIAGNOSES; GENITALIA; GENITALIA, MALE; HORMONES; LABORATORY EXAMINATIONS AND DIAGNOSES; MEASUREMENT; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; TESTIS; TESTOSTERONE--ADMINISTRACTION AND DOSAGE; TESTOSTERONE--ANALYSIS; UROGENITAL SYSTEM;

ADOLESCENT; ADULT; BIODEGRADATION; BIOLOGICAL AVAILABILITY; DRUG COMPOUNDING; HUMAN; HYPOGONADISM; INJECTIONS; LIPIDS; MALE; MIDDLE AGE; SEX HORMONES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TESTOSTERONE; TIME FACTORS;

EID: 0026568891     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.74.1.1727832     Document Type: Article

References (39)

1. Burris AS, Ewing LL, Sherins RJ. Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil Steril. 1988;50:493-7.
2. Lewis DH. Controlled release of bioactive agents from lactide/glycolide it polymers. In: Chasin M, Langer R, eds. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker; 1990;1-41.
3. Brady JM, Cutright DE, Miller RA, Battistone GC. Resorption rate, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. Biomed Mater Res. 1973;7:155-63.
4. Jockenhovel FF, Bhasin S, Steiner BS, Rivier JE, Vale WW, Swerdloff RS. Hormonal effects of single GnRH antagonist doses in men. Clin Endocrinol Metab. 1988;66:1065-70.
5. Bhasin S, Fielder T, Peacock N, Sod-Moriah UA, Swerdloff RS. Dissociating antifertility effects of GnRH antagonist from its adverse effects on mating behavior. Am Physiol. 1988;254:E84-91.
6. Vermuelen A, Stoica T, Verdonck L. The apparent free testosterone concentration: an index of androgenicity. Clin Endocrinol Metab. 1971;33:759-67.
7. Rao PN, Khan AH, Moore PH. Synthesis of new steroid haptens for radioimmunoassay. III. 15Betacarboxyethylmercaptosteroid-bovine serum albumin conjugates specific antisera for radioimmunoassay of 5-dihydrotestosterone 5-androstane-3 beta17betadiol, and 5-androstane-3,17-betadiol. Steroids. 1977;29:171-84.
8. Rosner W. A simplified method for the quantitative determination of testosterone estradiol-binding globulin activity in human plasma. J Clin Endocrinol Metab. 1972;34:983-8.
9. Lipid Research Clinics Program. Manual of laboratory operations. DHEW publication no. (NIH) 75-628. Washington DC: U.S. Government Printing Office; 1975;1.
10. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1976;17:182-5.
11. Gidez LI, Miller GJ, Burnstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982;23:1206-23.
12. Friedewald W, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
13. Karlin JB, Juhn DJ, Scanu AM, Rubenstein AM. Measurement of human serum lipoprotein B by radioimmunoassay. Eur J Clin Invest. 1978;8:19-26.
14. Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comp Prog Biomed. 1983;16:203-16.
15. Tishler A, Zang I. A new maximum likelihood algorithm for piecewise regression. J Am Stat Assoc. 1981;76:980-7.
16. Horton R, Shinsako J, Forshain PH. Testosterone production and metabolic clearance rates with volumes of distribution in normal adult men and women. Acta Endocrinol (Copenh). 1965;48:446-58.
17. Snyder PJ. Clinical use of androgens. Annu Rev Med. 1985;35:207-17.
18. Sokol RZ, Swerdloff RS. Practical consideratins in the use of androgen therapy: In: Santen RJ, Swerdloff RS, eds. Male reproductive dysfunction. New York: Marcel Dekker; 1986;211-25.
19. Nieschlag E. Current status of testosterone substitution therapy. Int J Androl. 1982;5:225-6.
20. Capell PT, Paulsen CA, Derleth DA, Skoglung R, Plymate S. The effect of short-term testosterone administration on serum FSH, LH, and testosterone levels: evidence for selective abnormalities in LH control in patients with Klinefelter’s syndrome. J Clin Endocrinol Metab. 1973;37:752-9.
21. Winters SJ, Sherins RJ, Loriaux DL. Studies on the role of sexsteroids and feedback control of gonadotropin concentration in men. III. Androgen resistance in primary gonadal failure. J Clin Endocrinol Metab. 1979;48:553-8.
22. Heiss G, Johnson NJ, Rellans S, Davis C, Tyroler HA. The epidemiology of plasma HDLC levels. Circulation. 1980;62(Suppl 4):116-36.
23. Morrison JA, deGroot I, Edwards BK, et al. Plasma cholesterol and triglyceride levels in 6,775 school children ages 6-17. Metabolism. 1977;26:1199-211.
24. Soloyom M. Effect of androgens on serum lipids and lipoproteins. Lipids. 1979;7:100-5.
25. Hurley BF, Seal DR, Hagberg JM, et al. HDLC in body builders and powerlifters. JAMA. 1984;252:507-13.
26. Friedl KE, Plymate SR, Paulsel CA. Transient reduction in serum HDL-cholesterol following medroxyprogesterone acetate and testosterone cypionate administration to healthy men. Contraception. 1985;31:409-20.
27. Goldberg RB, Rabin D, Alexander AN, Doelle GC, Getz GS. Suppression of plasma testosterone leads to an increase in serum total and HDLC and apoproteins A and B. J Clin Endocrinol Metab. 1985;60:203-7.
28. Haffner SM, Kushwaha RS, Foster DM, Applebaum DA, Hazzard WR. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 1983;32:413-20.
29. Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril. 1987;47:1004-9.
30. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 1980;51:1335-9.
31. Cantrill J, Dewis P, Large DM, Newmain M, Anderson DC. Which testosterone replacement therapy? Clin Endocrinol (Oxf). 1984;21:97-107.
32. Schulte-Beerbuhl M, Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril. 1980;33:201-3.
33. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982;37:425-30.
34. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 1990;71:216-22.
35. Weinbauer GF, Marshall GR, Nieschlag E. New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months. Acta Endocrinol (Copenh). 1986;113:128-32.
36. Korenman SG, Viosca S, Garza D, et al. Androgen therapy of hypogonadal men with trans-scrotal testosterone systems. Am J Med. 1987;83:471-8.
37. Ahmed SR, Boucher AE, Manni A, Santen R, Bartholomew M, Demers LM. Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab. 1988;66:546-51.
38. Schurmeyer TH, Wickings EJ, Freischem CW, Nieschlag E. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol (Copenh). 1983;102:456-62.
39. Nieschlag E, Cuppers HJ, Wiegelmann W, Wickings EJ. Bioavailability and LH suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res. 1976;7:138.